Abeona Therapeutics Inc. (NASDAQ:ABEO – Get Free Report) insider Madhav Vasanthavada sold 4,170 shares of the stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $5.43, for a total value of $22,643.10. Following the completion of the transaction, the insider owned 308,901 shares in the company, valued at $1,677,332.43. This represents a 1.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Madhav Vasanthavada also recently made the following trade(s):
- On Tuesday, June 9th, Madhav Vasanthavada sold 5,450 shares of Abeona Therapeutics stock. The stock was sold at an average price of $5.30, for a total value of $28,885.00.
- On Monday, May 11th, Madhav Vasanthavada sold 5,548 shares of Abeona Therapeutics stock. The stock was sold at an average price of $5.96, for a total value of $33,066.08.
Abeona Therapeutics Trading Up 3.2%
NASDAQ:ABEO opened at $5.53 on Friday. The stock’s 50 day moving average price is $5.42 and its 200 day moving average price is $5.17. Abeona Therapeutics Inc. has a 52 week low of $4.00 and a 52 week high of $7.54. The company has a market capitalization of $315.15 million, a P/E ratio of 5.70 and a beta of 1.35. The company has a debt-to-equity ratio of 0.03, a quick ratio of 5.70 and a current ratio of 5.89.
Analyst Ratings Changes
A number of equities analysts recently commented on the company. Stifel Nicolaus set a $17.00 price objective on Abeona Therapeutics in a report on Tuesday, March 17th. Oppenheimer restated an “outperform” rating on shares of Abeona Therapeutics in a report on Monday, March 9th. Wall Street Zen upgraded Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, June 1st. Finally, HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Abeona Therapeutics in a report on Thursday, May 28th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Abeona Therapeutics presently has a consensus rating of “Hold” and an average price target of $19.00.
View Our Latest Analysis on Abeona Therapeutics
Institutional Investors Weigh In On Abeona Therapeutics
A number of large investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada boosted its position in Abeona Therapeutics by 49.6% during the first quarter. Royal Bank of Canada now owns 6,500 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 2,155 shares during the period. Legato Capital Management LLC boosted its position in Abeona Therapeutics by 21.0% during the fourth quarter. Legato Capital Management LLC now owns 13,180 shares of the biopharmaceutical company’s stock worth $69,000 after purchasing an additional 2,290 shares during the period. Deutsche Bank AG boosted its position in Abeona Therapeutics by 6.2% during the fourth quarter. Deutsche Bank AG now owns 39,368 shares of the biopharmaceutical company’s stock worth $207,000 after purchasing an additional 2,303 shares during the period. Rangeley Capital LLC boosted its position in Abeona Therapeutics by 4.2% during the first quarter. Rangeley Capital LLC now owns 60,000 shares of the biopharmaceutical company’s stock worth $269,000 after purchasing an additional 2,400 shares during the period. Finally, LPL Financial LLC boosted its position in Abeona Therapeutics by 5.3% during the fourth quarter. LPL Financial LLC now owns 62,873 shares of the biopharmaceutical company’s stock worth $331,000 after purchasing an additional 3,165 shares during the period. Institutional investors own 80.56% of the company’s stock.
Abeona Therapeutics Company Profile
Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.
The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.
Featured Stories
- Five stocks we like better than Abeona Therapeutics
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
